Tyrosinase mRNA is expressed in human substantia nigra

Molecular Brain Research

Volumn 45, Issue 1, 1997, Pages 159-162

  Xu, Yimei ^a   Stokes, Alan H ^a   Freeman, Willard M ^a   Kumer, Sean C ^a   Vogt, Brent A ^a   Vrana, Kent E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Gene expression; Parkinson's disease; RNA; RT PCR; Substantia nigra; Tyrosinase

Indexed keywords

DOPAMINE; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ARTICLE; CEREBELLUM; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NERVE DEGENERATION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; BRAIN NEOPLASMS; CEREBELLUM; DNA PRIMERS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SHY-DRAGER SYNDROME; SUBSTANTIA NIGRA; TRANSCRIPTION, GENETIC;

EID: 0031127499     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00308-7     Document Type: Article

References (24)

1. [1] Battyani, Z., Xerri, L., Hassoun, J., Bonerandi, J.-J. and Grob, J.-J., Tyrosinase gene expression in human tissues, Pigment Cell Res., 6 (1993) 400-405.
2. [2] Beerman, F., Schmid, E. and Schutz, G., Expression of the mouse tyrosinase gene during embryonic development: recapitulation of the temporal regulation in transgenic mice. Proc. Natl. Acad. Sci. USA, 89 (1992) 2809-2813.
3. [3] Björklund, A. and Lindvall, O., Dopamine containing systems in the CNS. In A. Björklund and T. Hökfelt (Eds.), Handbook of Chemical Neuroanatomy, Vol. 2, Classical Neurotransmitters in the CNS, Part I. Eisevier, Amsterdam, The Netherlands, 1984, pp. 55-111.
4. [4] Foley, J.M. and Baxter, D., On the nature of pigment granule in the cells of the locus coeruleus and subslantia nigra, J. Neuropathol Exp. Neurol., 17 (1958) 586-589.
5. [5] Garai, J., Tiller, A.A. and Clark, J.H., Tyrosinase-like polypeptides in the uterus and in the central nervous system of rats. Steroids, 57 (1992) 183-188.
6. 3H]dopamine: impact of ascorbic acid and glutathione, J. Neurochem., 63 (1994) 1126-1132.
7. [7] Hastings, T.G., Enzymatic oxidation of dopamine: the role of prostaglandin H synthase, J. Neurochem., 64 (1995) 919-924.
8. [8] Hearing, V.J. and Tsukamoto, K., Enzymatic control of pigmentation in mammals [review], FASEB, 5 (1991) 2902-2909.
9. [9] Herrero, M.T., Hirsch, E.C., Kastner, A., Ruberg, M., Luquin, M.R., Laguna, J., Javoy-Agid, F., Obeso, J.A. and Agid, Y., Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience, 56 (1993) 499-511.
10. [10] Kastner, A., Hirsch, E.C., Lejeune, O., Javoy-Agid, F., Rascol, O. and Agid, Y., Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem., 59 (1992) 1080-1089.
11. [11] King, R.A. and Witkop, Jr., C.J., Hairbulb tyrosinase activity in oculocutaneus albinism, Nature, 263 (1976) 69-71.
12. [12] Korner, A. and Pawelek, J., Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin, Science, 217 (1982) 1163-1165.
13. [13] Levay, G. and Bodell, W.J., Detection of dopamine-DNA adducts: potential role in Parkinson's disease, Carcinogenesis, 14 (1993) 1241-1245.
14. [14] Marsden, C.D., Brain melanin. In Wolman (Ed.), Pigment Pathology. Academic Press, New York, NY, 1969, pp. 395-420.
15. [15] Michel, P.P. and Hefti, F., Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture, J. Neurosci. Res., 26 (1990) 428-435.
16. [16] Miranda, M., Botti, D., Bonfigli, A., Ventura, T. and Arcadi, A., Tyrosinase-like activity in normal human substantia nigra, Gen. Pharmacol., 15 (1984) 541-544.
17. [17] Rodgers, A.D. and Curzon, G., Melanin formation by human brain in vitro, J. Neurochem., 24 (1975) 1123-1129.
18. [18] Rodriguez-Lopez, J.N., Varon, R. and Garcia-Canovas, F., Oxidation of 6-hydroxydopamine catalyzed by tyrosinase, Int. J. Biochem., 25 (1993) 1175-1182.
19. [19] Sanchez-Ferrer, A., Rodriguez-Lopez, J.N., Garcia-Canovas, F. and Garcia-Carmona, F., Tyrosinase: a review of its mechanism. Biochim. Biophys. Acta, 1247 (1995) 1-11.
20. [20] Sanger, F., Nicklen, S. and Coulson, A.R., DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467.
21. [21] Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C. and Blair, G.E., Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction, Lancet, 338 (1991) 1227-1229.
22. [22] Stokes, A.H., Brown, B.G., Lee, C.K., Doolittle, D.J. and Vrana, K.E., Tyrosinase enhances the covalent modification of DNA by dopamine. Mol. Brain Res., 42 (1996) 167-170.
23. [23] Tief, K., Schmidt, A., Aguzzi, A. and Beerman, F., Tyrosinase is a new marker for cell populations in the mouse neural tube, Dev. Dynam., 205 (1996) 445-456.
24. [24] Vrana, S.L., Kluttz, B.W. and Vrana, K.E., Application of quantitative RT-PCR to the analysis of dopamine receptor mRNA levels in rat striatum, Mol. Brain. Res., 34 (1995) 127-134.